Actualités et communiqués de presse Zymeworks 2026 | ZYME | ISIN US98985Y1082

Actualités Eulerpool Zymeworks

Actualités de l'action Zymeworks

Zymeworks est suivi par de nombreux journalistes et investisseurs dans le monde. Nous rassemblons ici les dernières actualités concernant Zymeworks.

18 septembre·
SeekingAlpha
Zymeworks' Theravance Deal Is A Breath Of Fresh Cash Flow
12 février·
Yahoo
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
22 janvier·
SeekingAlpha
Zymeworks Inc. (ZYME) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
17 décembre·
Benzinga
Truist Securities Initiates Coverage On Zymeworks with Buy Rating, Announces Price Target of $40
3 décembre·
Benzinga
Citizens Initiates Coverage On Zymeworks with Market Outperform Rating, Announces Price Target of $32
21 novembre·
SeekingAlpha
Zymeworks: Adjusting My Levels After Ziihera's Phase III Data For GEA
20 novembre·
SeekingAlpha
Zymeworks Inc. 2025 Q3 - Results - Earnings Call Presentation
19 novembre·
SeekingAlpha
Zymeworks: A Lot Of Moving Parts
19 novembre·
Benzinga
Wells Fargo Maintains Equal-Weight on Zymeworks, Raises Price Target to $25
19 novembre·
Benzinga
Stifel Maintains Buy on Zymeworks, Raises Price Target to $40
17 novembre·
SeekingAlpha
Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise
17 novembre·
SeekingAlpha
Zymeworks Surges On Positive Ziihera Phase 3 Data: Expanding First-Line GEA Opportunity
17 novembre·
Benzinga
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans
17 novembre·
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
17 novembre·
Benzinga
Zymeworks And Partners Report Statistically Significant And Clinically Meaningful Improvements Across PFS OS ORR And DoR In HERIZON GEA 01
7 novembre·
Benzinga
Wells Fargo Maintains Equal-Weight on Zymeworks, Raises Price Target to $17
7 novembre·
SeekingAlpha
Zymeworks Inc. (ZYME) Q3 2025 Earnings Call Transcript
4 novembre·
Yahoo
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
4 novembre·
Yahoo
A Look at Zymeworks (ZYME) Valuation After 50% Share Price Rally Over 3 Months
30 octobre·
Yahoo
Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Communiqués de presse relatifs à l'action Zymeworks

Zymeworks publie régulièrement sur son site web des communiqués pertinents pour les investisseurs.

25 janvier•
Zymeworks
Zymeworks Announces Participation in Upcoming Investor Conferences
4 janvier•
Zymeworks
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023
21 décembre•
Zymeworks
Zymeworks Announces Participation in Upcoming Investor Conference
19 décembre•
Zymeworks
Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab
14 décembre•
Zymeworks
Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
9 décembre•
Zymeworks
New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS
5 décembre•
Zymeworks
Zymeworks to Transfer Stock Listing to Nasdaq
29 novembre•
Zymeworks
Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals
22 novembre•
Zymeworks
Zymeworks Announces Participation in Upcoming Investor Conference
21 novembre•
Zymeworks
Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)
8 novembre•
Zymeworks
Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results
20 octobre•
Zymeworks
Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and Applications of Proprietary Next-Generation Technology Platforms
18 octobre•
Zymeworks
Zymeworks to Host Third Quarter Results Conference Call
13 octobre•
Zymeworks
Zymeworks Completes Plan to Become Delaware Corporation
7 octobre•
Zymeworks
Zymeworks Announces Results of Special Meeting
4 octobre•
Zymeworks
Zymeworks Reminds Shareholders to Vote FOR its Redomicile
3 octobre•
Zymeworks
Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development Day
26 septembre•
Zymeworks
Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile
16 septembre•
Zymeworks
Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR Redomicile
12 septembre•
Zymeworks
Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress
8 septembre•
Zymeworks
Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware
4 septembre•
Zymeworks
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers
4 août•
Zymeworks
Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results
1 août•
Zymeworks
Zymeworks Announces Participation in Upcoming Investor Conferences
25 juillet•
Zymeworks
Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris
22 juillet•
Zymeworks
Zymeworks Reports Inducement Grant to New Chief Scientific Officer
21 juillet•
Zymeworks
Zymeworks to Host Second Quarter Results Conference Call
15 juillet•
Zymeworks
Zymeworks Announces Plan to Become a Delaware Corporation
27 juin•
Zymeworks
Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
10 juin•
Zymeworks
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company

Zymeworks News 2026

Cette page contient toutes les actualités actuelles, analyses et communiqués de presse pour l'action Zymeworks (ZYME, ISIN : US98985Y1082). Cela inclut les actualités Eulerpool, les analyses d'entreprise et les communiqués de presse officiels. Les données sont mises à jour régulièrement pour fournir aux investisseurs un aperçu complet des derniers développements chez Zymeworks.